Skip to content Skip to footer
Subscribe Now
Biocon Biologics
NEWS

Biocon Biologics and Regeneron Settle over Yesafili’s (Biosimilar, Eylea) US Launch

Shots:Biocon Biologics & Regeneron have entered into a settlement & license agreement, allowing the US launch of Yesafili, an interchangeable biosimilar version of Eylea (aflibercept) by H2’26Yesafili’s FDA approval was supported by analytical, nonclinical & clinical data incl. P-III (INSIGHT) trial assessing Yesafili vs Eylea in DME pts, confirming its similarity in PK,…
April 16, 2025

Read more

Top Performing Drugs: Proceeding the Series
INSIGHTS+

Top Performing Drugs: Proceeding the Series

Shots:Subsequent to our last year’s series titled “Top Performing Drugs of 2021”, PharmaShots presents a list of 12 high revenue-generating drugsWith the ongoing pandemic playing an instrumental role in reshaping the life science industry now and then, it becomes increasingly onerous for the pharmaceutical industry to keep up with the growing global demands…
April 25, 2023

Read more

Exclusive_John Meduri_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and worldwide. He also shared his views on Accelerate Pheno system and PhenoTest BC kit.Shots:Antibiotic resistance occurs when bacteria develop the ability to defeat…
February 14, 2022

Read more

Viewpoints_Chris Arendt
VIEWPOINTS

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLCShots:The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitorThe results showed…
November 22, 2021

Read more

Viewpoints_Lloyd Miller
VIEWPOINTS

PharmaShots Interview: Janssen’s Lloyd Miller Shares Insight on the Data of Tremfya (guselkumab) Presented at EADV 2021

In an interview with PharmaShots, Lloyd Miller, MD, Ph.D., Vice President, Immunodermatology Disease Area Leader at Janssen shares his views on the data presented at EADV 2021 about patients who switch to Tremfya (guselkumab) from Humira (adalimumab) in P-III VOYAGE 1 & 2 trials for PsO & also highlighting the P-III DISCOVER-1 & 2 trial for PsAShots:The P-III VOYAGE 1 &…
November 10, 2021

Read more

Viewpoints_Laurent Debussche
VIEWPOINTS

PharmaShots Interview: Sanofi’s Laurent Debussche Shares Insight on the Need of SERDs for ER+ Breast Cancer

In an interview with PharmaShots, Laurent Debussche, Global Head of Molecular Oncology Research Therapeutic Area at Sanofi shares insight on the SERDs data being presented at ASCO 2021 and highlight the need for this type of innovation for ER+ breast cancerShots:Sanofi has presented the data from P-I AMEERA-1 study evaluating amcenestrant in combination with palbociclib &…
August 9, 2021

Read more

Viewpoints_Douglas E. Williams
VIEWPOINTS

PharmaShots Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes

In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020.Shots:Codiak demonstrated the potential of engineered exosomes -  extracellular vesicles that act like the body's FedEx delivery trucks to carry messengers between cells -…
April 20, 2021

Read more

Load more